Boston Trust Walden Corp Grows Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Posted by Defense World Staff on Mar 31st, 2023

Boston Trust Walden Corp increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Get Rating) by 50.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,932 shares of the medical research company’s stock after buying an additional 651 shares during the quarter. Boston Trust Walden Corp’s holdings in Thermo Fisher Scientific were worth $1,064,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Verity & Verity LLC raised its position in shares of Thermo Fisher Scientific by 2.8% during the 2nd quarter. Verity & Verity LLC now owns 1,234 shares of the medical research company’s stock valued at $670,000 after buying an additional 34 shares during the period. Roffman Miller Associates Inc. PA raised its position in Thermo Fisher Scientific by 0.5% in the fourth quarter. Roffman Miller Associates Inc. PA now owns 31,116 shares of the medical research company’s stock valued at $17,135,000 after purchasing an additional 166 shares during the period. Merit Financial Group LLC raised its position in Thermo Fisher Scientific by 36.3% in the fourth quarter. Merit Financial Group LLC now owns 5,583 shares of the medical research company’s stock valued at $3,075,000 after purchasing an additional 1,486 shares during the period. SVB Wealth LLC raised its position in Thermo Fisher Scientific by 3.8% in the second quarter. SVB Wealth LLC now owns 7,390 shares of the medical research company’s stock valued at $4,015,000 after purchasing an additional 273 shares during the period. Finally, Western Financial Corp CA purchased a new stake in Thermo Fisher Scientific in the fourth quarter valued at approximately $627,000. Hedge funds and other institutional investors own 85.92% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on TMO shares. Morgan Stanley boosted their target price on Thermo Fisher Scientific from $613.00 to $670.00 and gave the company an “overweight” rating in a research report on Thursday, February 2nd. Robert W. Baird cut their price objective on Thermo Fisher Scientific from $710.00 to $693.00 in a research report on Thursday, February 2nd. Wells Fargo & Company cut their price objective on Thermo Fisher Scientific from $525.00 to $505.00 and set an “underweight” rating on the stock in a research report on Tuesday, January 3rd. Barclays upped their price objective on Thermo Fisher Scientific from $630.00 to $660.00 and gave the stock an “overweight” rating in a research report on Thursday, February 2nd. Finally, Citigroup upped their price objective on Thermo Fisher Scientific from $650.00 to $700.00 and gave the stock a “buy” rating in a research report on Thursday, February 2nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average price target of $647.00.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, Director Jim P. Manzi sold 1,000 shares of the company’s stock in a transaction on Friday, February 3rd. The shares were sold at an average price of $584.56, for a total value of $584,560.00. Following the completion of the transaction, the director now owns 14,807 shares in the company, valued at $8,655,579.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Jim P. Manzi sold 1,000 shares of the company’s stock in a transaction dated Friday, February 3rd. The shares were sold at an average price of $584.56, for a total value of $584,560.00. Following the completion of the sale, the director now directly owns 14,807 shares of the company’s stock, valued at $8,655,579.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Marc N. Casper sold 20,000 shares of the company’s stock in a transaction dated Friday, February 10th. The shares were sold at an average price of $569.18, for a total transaction of $11,383,600.00. Following the completion of the sale, the chief executive officer now directly owns 128,705 shares of the company’s stock, valued at $73,256,311.90. The disclosure for this sale can be found here. Insiders sold 30,100 shares of company stock worth $16,966,971 over the last 90 days. Corporate insiders own 0.43% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $562.97 on Friday. The company has a current ratio of 1.48, a quick ratio of 1.15 and a debt-to-equity ratio of 0.66. The firm has a fifty day moving average price of $562.14 and a 200 day moving average price of $545.33. The company has a market cap of $216.99 billion, a P/E ratio of 31.93, a PEG ratio of 1.87 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 12 month low of $475.77 and a 12 month high of $618.35.

Thermo Fisher Scientific (NYSE:TMO – Get Rating) last released its quarterly earnings data on Wednesday, February 1st. The medical research company reported $5.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.19 by $0.21. Thermo Fisher Scientific had a net margin of 15.47% and a return on equity of 21.42%. The company had revenue of $11.45 billion during the quarter, compared to the consensus estimate of $10.41 billion. During the same quarter in the prior year, the firm posted $6.54 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up 7.0% on a year-over-year basis. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.72 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 14th. Shareholders of record on Wednesday, March 15th will be paid a $0.35 dividend. This represents a $1.40 annualized dividend and a yield of 0.25%. The ex-dividend date of this dividend is Tuesday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.30. Thermo Fisher Scientific’s dividend payout ratio is currently 7.94%.

Thermo Fisher Scientific Company Profile

(Get Rating)

Thermo Fisher Scientific, Inc engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Get Rating).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.